Physician profile
Mark D Deponte
NPI 1265434583
$8,313.48
in general payments reported to CMS, 2019-2025
27 companies · $1,316 in 2025
The $1,316 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $614 · 2020: $833 · 2021: $1,447 · 2022: $1,206 · 2023: $1,432 · 2024: $1,465 · 2025: $1,316.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,214.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,213.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,476.08 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Novo Nordisk INC | $1,365.87 | 2019-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $1,280.61 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $683.57 | 2019-2025 | Farxiga, Breztri |
| Astellas Pharma US INC | $478.05 | 2019-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $455.74 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $365.02 | 2020-2025 | Rexulti |
| Allergan, INC. | $305.44 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $262.91 | 2020-2025 | Jardiance, Synjardy, Tradjenta |
| Lundbeck LLC | $236.91 | 2022-2025 | Rexulti |
| Amgen INC. | $202.46 | 2022-2025 | Repatha, Otezla, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $192.82 | 2019-2025 | Xifaxan, Trulance |
| Eisai INC. | $142.97 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $136.80 | 2019-2023 | Vaxneuvance, Gardasil 9, Pneumovax 23 |
| Novartis Pharmaceuticals Corporation | $127.98 | 2019-2024 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $110.63 | 2024-2025 | Voquezna |
| Exact Sciences Corporation | $100.32 | 2023-2024 | Cologuard Collection Kit |
| Endo Pharmaceuticals INC. | $96.18 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $68.28 | 2021 | |
| Abbott Laboratories | $59.84 | 2023-2024 | Freestyle Libre 3 |
| Corcept Therapeutics | $49.22 | 2024 | Korlym |
| Amarin Pharma, INC. | $32.97 | 2020-2022 | |
| Alexion Pharmaceuticals, INC. | $20.50 | 2021 | |
| Lilly USA, LLC | $16.79 | 2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $15.90 | 2020 | |
| Idorsia Pharmaceuticals US INC | $15.08 | 2024 | Quviviq |
| Kowa Pharmaceuticals America, INC. | $14.54 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Deponte listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.